Novaccess Global Inc XSNX

Healthcare Biotechnology

NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.

OTCPK:XSNX - Post by User

Novaccess Global Inc

Bullboard Posts

Comment by optiprimeon Mar 17, 2011 11:09am

283 Views

Post# 18298620

RE: Closer to Commercializing

XsunX Inc. (OTC: XSNX) is up 25.00% to
.105 on volume of 2.10 million shares. The solar technology developer on Monday announced that it has entered into an agreement with Globe Future for the purchase of manufacturing systems and an operating license for XSNX’s CIGSolar technology. (OTC:XSNX), (XSNX)